(TERN) Terns Pharmaceuticals - Ratings and Ratios

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development of small-molecule therapeutics targeting high-unmet medical needs in oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its pipeline includes three key candidates: TERN-701, TERN-501, and TERN-601. TERN-701 is an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) currently in a Phase 1 clinical trial for chronic myeloid leukemia (CML), a hematologic malignancy originating in the bone marrow. TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability, is in a Phase IIa clinical trial for MASH, a severe form of non-alcoholic fatty liver disease (NAFLD). TERN-601 is an orally administered small-molecule Glucagon-Like Peptide-1 (GLP-1) receptor agonist under development for obesity. Founded in 2016 and headquartered in Foster City, California, the company focuses on innovative approaches to address complex diseases.

The stock trades on the NASDAQ under the ticker symbol TERN. As of the latest data, the stock is priced at $3.69 with a 20-day average volume of 1,335,967 shares. The stocks moving averages stand at $4.17 (SMA20), $4.83 (SMA50), and $6.79 (SMA200), with an Average True Range (ATR) of $0.27. The company has a market capitalization of $340.18 million, with a price-to-book (P/B) ratio of 0.96. The forward P/E is 0.00, and the price-to-sales (P/S) ratio is 302.64. The return on equity (RoE) is reported at -24.16.